ArticleJournal of neurology2026
Impact of blood p-tau217 testing on diagnosis and diagnostic confidence in cognitive disorders: a real-world clinical study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe blood biomarker p-tau217 has demonstrated high accuracy in predicting underlying Alzheimer's disease (AD) pathology. However, its feasibility and impact on clinician confidence and diagnosis in real-world clinical settings remain underexplored. We aimed to evaluate the effect of implementing blood p-tau217 testing on both diagnosis and diagnostic confidence in patients with cognitive symptoms across two different clinical settings: general neurology consultations referred from primary care and a specialized memory unit.
methodsWe included 200 consecutive new patients (38.5% with subjective cognitive complaints, 47.5% mild cognitive impairment, and 14% with dementia) evaluated for cognitive symptoms in two distinct clinical settings: general neurology and a memory unit. Attending neurologists were asked to record a pre-biomarker clinical diagnosis and their diagnostic confidence on a scale from 0 to 10. They repeated this assessment after receiving the p-tau217 results.
resultsAcross the whole sample, 51/200 patients (25.5%) had a change in their diagnostic category after receiving p-tau217 levels. Furthermore, diagnostic confidence significantly improved from 6.90 ± 1.74 at the first visit to 8.49 ± 1.68 after the test. Changes in diagnosis and confidence were observed in both general neurology and memory unit settings, and across all clinical stages (subjective cognitive complaints, mild cognitive impairment, and dementia). Compared with the final diagnosis, the pre-biomarker diagnosis was maintained in 71/200 cases (75.5%) (Kappa = 0.576), while the post-biomarker diagnosis was maintained in 189/200 cases (94.5%) (Kappa = 0.906).
conclusionsImplementing p-tau217 in real-world clinical practice has a strong clinical impact, substantially improving diagnostic accuracy and confidence in both general neurology and memory units across all stages of cognitive decline.
Indexed as
Identifiers
41665822What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.